Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Rheumatology
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2002; 41: 358
© 2002 British Society for Rheumatology

Robin Goodfellow

The first 10% of the full text of this article appears below.

NICE to see you. Devotees of Bruce Forsyth's ‘Generation Game’ (yes, Robin liked his light relief when he was a young man) may now find a different meaning in this catch-phrase, but is it nice to see NICE (National Institute for Clinical Excellence)? Robin wants to know what rheumatologists think of their injunction not to co-prescribe gastroprotective drugs with COX-2 selective agents. Latest advice is that guidelines will be obligatory, courtesy of a new Bill to pass before parliament. Suppose, he reasons, that you have a patient who has had side-effects on standard non-steroidal anti-inflammatory drugs (NSAIDs), an ulcer even, and gets indigestion on meloxicam, etodolac . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Rheumatology:

Keeping our patients at work: implications for the management of those with rheumatoid arthritis and musculoskeletal conditions
A. O. Frank and M. A. Chamberlain
Rheumatology 2001 40: 1201-1205. [Extract] [FREE Full Text]